newsfilter
← Latest News
GlobeNewswire·

Day One Reports Second Quarter 2025 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) net product revenue of $33.6 million in Q2 2025, a 10% quarter-over-quarter increase OJEMDA full-year 2025 net product revenue expected to be $140 to $150 million Ended the second quarter